title: Blood pressure control in ultra-early basal ganglia intracerebral hemorrhage.
abstract: OBJECTIVE
  We performed this study to investigate the effect of blood pressure control in ultra-early basal ganglia intracerebral hemorrhage.
  
  
  METHODS
  120 patients with ultra-early basal ganglia intracerebral hemorrhage were randomly divided into experimental group (strengthened antihypertensive) and control (normal antihypertensive). Each group consists of 60 patients, whose contractive pressure were controlled by intravenous antihypertensive drugs among 130-140 mmHg and 160-180 mmHg respectively for 24 h, after 1 h of beginning treatment. They were all evaluated by NIH Stroke Scale (NIHSS) before and after the treatment. Cranial CT, hematoma volume, hematoma enlargement, edema volume, serum matrix metalloproteinase-9 level were performed and compared between groups.
  
  
  RESULTS
  After 24 h, hematoma volume and hematoma enlargement in the experimental group was significantly lower than control (p < 0.05). After 14 days, NIHSS score in the experimental group was significantly lower than control (p < 0.05). Cerebral edema amount and serum MMP-9 level in the experimental group were significantly lower than control after 5 days and 14 days.
  
  
  CONCLUSIONS
  Ultra-early basal ganglia intracerebral hemorrhage can remarkably reduce hematoma enlargement, cerebral edema, serum MMP-9 level, and improve the neurological function.
authors.affiliation: Department of Neurology, Qilu Hospital, Shandong University, Jinan, Shandong, China. czyan@sdu.edu.cn.
authors.forename: F T
authors.initials: FT
authors.lastname: Gong
authors.forename: L P
authors.initials: LP
authors.lastname: Yu
authors.forename: Y H
authors.initials: YH
authors.lastname: Gong
authors.forename: Y X
authors.initials: YX
authors.lastname: Zhang
authors.forename: Z G
authors.initials: ZG
authors.lastname: Wang
authors.forename: C Z
authors.initials: CZ
authors.lastname: Yan
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001479:Basal Ganglia / Q000187:drug effects / Q000473:pathology*; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology*; D001929:Brain Edema / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D002543:Cerebral Hemorrhage / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006406:Hematoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D020780:Matrix Metalloproteinase 9